Table 2.
Clinical Assessment
| Allo-HSCT (n = 104) | Control Subjects (n = 55) | p Value | |
|---|---|---|---|
| New York Heart Association functional class∗ | |||
| I | 74 (72.5) | 55 (100) | <0.001 |
| II | 16 (15.7) | 0 (0.0) | 0.002 |
| III | 12 (11.8) | 0 (0.0) | 0.009 |
| Comorbidities | |||
| Hypertension | 42 (40.4) | 1 (1.8) | <0.001 |
| Diabetes mellitus | 3 (2.9) | 0 (0.0) | 0.552 |
| Hypothyroidism | 10 (9.6) | 0 (0.0) | 0.016 |
| Hypercholesterolemia | 16 (15.4) | 0 (0.0) | 0.002 |
| Smoking (current/previous)∗ | 10 (9.8)/18 (17.6) | 2 (3.6)/11 (20.0) | 0.165/0.717 |
| Cardiovascular medications | 33 (31.7) | 0 (0.0) | <0.001 |
| Statins | 4 (3.8) | 0 (0.0) | — |
| Calcium-channel blockers | 13 (12.5) | 0 (0.0) | — |
| Beta-blockers | 13 (12.5) | 0 (0.0) | — |
| Angiotensin-converting enzyme inhibitors | 7 (6.7) | 0 (0.0) | — |
| Angiotensin receptor blockers | 13 (12.5) | 0 (0.0) | — |
| Laboratory parameters | |||
| Troponin T >14 ng/l | 3 (2.9) | 0 (0.0)† | 0.551 |
| Elevated NT-proBNP‡ | 17 (16.3) | 2 (4.0)† | 0.029 |
| HDL cholesterol, mmol/l§ | 1.5 ± 0.4 | 1.7 ± 0.5† | 0.051 |
| LDL cholesterol, mmol/l§ | 3.1 ± 0.8 | 3.0 ± 0.9† | 0.433 |
Values are n (%) or mean ± SD.
allo-HSCT = allogeneic hematopoietic stem cell transplantation; HDL = high-density lipids; LDL = low-density lipids; NT-proBNP = N-terminal pro–B-type natriuretic peptide.
∗
2 absences in findings.
†
n = 50.
‡
Elevated = age 18 to 44 years: men >86 ng/l, women >130 ng/l; age 45 to 54 years: men >121 ng/l, women >249 ng/l.
§
Conversion rate to mg/dl = mmol/l × 38.66 (Roche Diagnostics, Basel, Switzerland).